



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/501,726

07/16/2004

Renate Kunert

3224-153

4370

6449

7590

11/17/2008

ROTHWELL, FIGG, ERNST & MANBECK, P.C.

1425 K STREET, N.W.

SUITE 800

WASHINGTON, DC 20005

EXAMINER

PARKIN, JEFFREY S

ART UNIT

PAPER NUMBER

1648

NOTIFICATION DATE

DELIVERY MODE

11/17/2008

ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

PTO-PAT-Email@rfem.com

Office Action Summary	Application No. 10/501,726	Applicant(s) KUNERT ET AL.	
	Examiner Jeffrey S. Parkin	Art Unit 1648	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 03 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 21 July 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-3,6-10,12,13 and 19 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3,6-10,12,13 and 19 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--------------------------------------------------------------------------------------|-------------------------------------------------------------------|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

Application No.: 10/501,726
Applicants: Kunert, R., et al.

Docket No.: 3224-153
Filing Date: 07/16/2004

Detailed Office Action

Status of the Claims

Acknowledgement is hereby made of receipt and entry of the communication filed 21 July, 2008. Claims 1-3, 6-10, 12, 13, and 19 are pending in the instant application.

35 U.S.C. § 101

The following is a quotation of 35 U.S.C. § 101 which reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title.

The previous rejection of claim 12 under 35 U.S.C. § 101 because the claimed invention is directed toward non-statutory subject matter, is hereby withdrawn in response to applicants' amendment.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Application No.: 10/501,726
Applicants: Kunert, R., et al.

Docket No.: 3224-153
Filing Date: 07/16/2004

Biological Deposit Requirement

The previous rejection of claims 1, 5, and 11 under 35 U.S.C. § 112, first paragraph, as failing to provide an enabling disclosure for the claimed invention, is hereby withdrawn in response to applicants' amendment.

35 U.S.C. § 112, Second Paragraph

The following is a quotation of the second paragraph of 35 U.S.C. § 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

The previous rejection of claims 6 and 13 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention, is hereby withdrawn in response to applicants' arguments/amendment.

Claims 1-3, 6-10, 12, 13, and 19 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Applicants' response as it pertains to the aforementioned biological deposit requirement has been noted. However, applicants' response creates some ambiguity and confusion concerning the nature of the deposit set forth for Mab 2F5 (ECACC Accession No. 90091704). It appears that this designation is directed toward the **hybridoma** cell line producing Mab 2F5, not the Mab itself. If this interpretation is correct, amendment of the claims to

Application No.: 10/501,726
Applicants: Kunert, R., et al.

Docket No.: 3224-153
Filing Date: 07/16/2004

recite that Mab 2F5 is produced by the hybridoma cell line having the ECACC Accession No. 90091704 would be remedial.

35 U.S.C. § 103(a)

The following is a quotation of 35 U.S.C. § 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The previous rejection of claims 1-4, 7-10, 12, and 13 under 35 U.S.C. § 103(a) as being unpatentable over Kang (1991) in view of Muster et al. (1993), is hereby withdrawn in response to applicants' amendment.

Allowable Subject Matter

Claims 1-3, 6-10, and 19 appear to be free of the prior art of record. Appropriate amendment of the claim language as suggested *supra* to ameliorate the remaining issues under 35 U.S.C. § 112, second paragraph, would result in an allowance.

35 U.S.C. § 112, First Paragraph

The following is a quotation of the first paragraph of 35 U.S.C. § 112:

The specification shall contain a written description of the invention, and of the manner and process of making and

using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Enablement

Claims 12 and 13 are rejected under 35 U.S.C. § 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Claim 12 is directed toward a method for the prophylaxis or treatment of HIV-1 infection by administering a Mab that is anti-idiotypic to Mab 2F5 and has the characteristics of Mab 3H6. Claim 13 is directed toward a pharmaceutical composition or vaccine comprising said antibody. The premise of the invention is directed toward the administration of an anti-idiotypic antibody (Ab2) to a patient. Ab2 was generated against an HIV-1 neutralizing Mab (Ab1) designated Mab 2F5. Thus, Ab2 upon administration to patients may act as a competitive/noncompetitive inhibitor of Ab1 or it may act as an antigen to induce the formation of anti-anti-idiotypic antibodies (Ab3) that have similar properties to the parental antibody (Ab1). Moreover, the disclosure states that "In principle, Ab2 beta antibodies raised against antibodies neutralizing HIV-1 might have an enormous potential for vaccine design" (p. 3). Thus, applicants are clearly interested in employing the claimed compositions as immunogens in a vaccinating composition.

The legal considerations that govern enablement determinations pertaining to undue experimentation have been clearly set forth. *Enzo Biochem, Inc.*, 52 U.S.P.Q.2d 1129 (C.A.F.C. 1999). *In re Wands*, 8 U.S.P.Q.2d 1400 (C.A.F.C. 1988). *Ex parte Forman* 230 U.S.P.Q. 546 (PTO Bd. Pat. App. Int., 1986). The courts concluded that several factual inquiries should be considered when making such assessments including the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims. *In re Rainer*, 52 C.C.P.A. 1593, 347 F.2d 574, 146 U.S.P.Q. 218 (1965). The disclosure fails to provide adequate guidance pertaining to a number of these considerations as follows:

- 1) The disclosure fails to provide adequate guidance pertaining to the correlates of human protection and methods for eliciting protective/therapeutic immune responses. To date, it is not currently known what type of immune response will provide a protective/therapeutic outcome.
- 2) The disclosure fails to provide any guidance pertaining to the immunologic/pharmacologic properties of any given therapeutic Mab. The disclosure fails to provide detailed guidance pertaining to the binding specificity, coding potential, affinity, specificity, titer, and pharmacological profile of any given therapeutic Mab.
- 3) The disclosure fails to provide any working embodiments demonstrating that administration of an anti-idiotypic antibody

(e.g., Mab 3H6) or an anti-anti-idiotypic antibody is capable of providing a therapeutic or protective outcome. Considering the unpredictability of the prior art, multiple working embodiments would be required to enable the claimed invention. However, the specification fails to provide any data pertaining to the administration of Ab2 or the generation of therapeutic Ab3.

4) The state-of-the-art vis-à-vis HIV vaccine development is one of unpredictability (Moore and Burton, 1999; Haynes *et al.*, 2005; Montefiori, 2005; Trkola *et al.*, 2005; Gallo, 2005; Walker and Burton, 2008). Several problems have hampered the development of an efficacious HIV vaccine including the following: 1) The correlates of human protection remain to be elucidated. 2) It is not readily manifest which immunogens, carriers, adjuvants, and immunization regimen should be employed in the generation of a therapeutic/prophylactic immune response. 3) There are currently no animal models that allow direct extrapolations of vaccine efficacy. 4) HIV-1 and -2 exist as a quasispecies that leads to immune avoidance and rapid immune escape. 5) HIV can reside in a number of different reservoirs in a latent state, thereby avoiding detection. 6) It is not readily manifest how to generate a long-lasting high-titer immune response to HIV.

Moore and Burton (1999) suggests that it might not be possible to generate Nabs of the requisite titer and specificity to effectively combat HIV-1 infection. This is because experimental animal data suggests that partial neutralization (i.e., 90% neutralization) is insufficient to inhibit HIV-1 infection. It may well require 100% neutralization, a figure not currently seen. Haynes *et al.* (2005) identifies some of the

Application No.: 10/501,726
Applicants: Kunert, R., et al.

Docket No.: 3224-153
Filing Date: 07/16/2004

problems with using Nab 2F5 as a target. This Mab is a polyspecific autoantibody that also reacts with the phospholipid cardiolipin. The author concluded (see Abstract, p. 1906) that "current HIV-1 vaccines may not induce these types of antibodies because of autoantigen mimicry of the conserved membrane-proximal epitopes of the virus." Trkola et al. (2005) note that it will be difficult to generate high-titer Nabs with the desired specificity. Moreover, the vast majority of patients in a passive antibody study displayed viral rebound and immune escape in a short period of time. Thus, it is not readily manifest how effective Nabs will be at combating HIV-1 infection. Montefiori (2005) also concluded that it will be extremely difficult to generate high-titer Nabs with the desired specificity.

Accordingly, when all the aforementioned factors are considered in toto, it would clearly require undue experimentation from the skilled artisan to practice the claimed invention.

Correspondence

Any inquiry concerning this communication should be directed to Jeffrey S. Parkin, Ph.D., whose telephone number is (571) 272-0908. The examiner can normally be reached Monday through Thursday from 10:30 AM to 9:00 PM. A message may be left on the examiner's voice mail service. If attempts to reach the examiner are unsuccessful, the examiner's supervisor, Bruce R. Campell, Ph.D., can be reached at (571) 272-0974. Direct general status inquiries to the Technology Center 1600 receptionist at (571) 272-1600. Informal communications may be submitted to the Examiner's RightFAX account at (571) 273-0908.

Applicants are reminded that the United States Patent and Trademark Office (Office) requires most patent related correspondence to be: a) faxed to the Central FAX number (571-

Application No.: 10/501,726
Applicants: Kunert, R., et al.

Docket No.: 3224-153
Filing Date: 07/16/2004

273-8300) (updated as of July 15, 2005), b) hand carried or delivered to the Customer Service Window (now located at the Randolph Building, 401 Dulany Street, Alexandria, VA 22314), c) mailed to the mailing address set forth in 37 C.F.R. § 1.1 (e.g., P.O. Box 1450, Alexandria, VA 22313-1450), or d) transmitted to the Office using the Office's Electronic Filing System. This notice replaces all prior Office notices specifying a specific fax number or hand carry address for certain patent related correspondence. For further information refer to the Updated Notice of Centralized Delivery and Facsimile Transmission Policy for Patent Related Correspondence, and Exceptions Thereto, 1292 Off. Gaz. Pat. Office 186 (March 29, 2005).

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Respectfully,

/Jeffrey S. Parkin/

Jeffrey S. Parkin, Ph.D.
Primary Examiner
Art Unit 1648

08 November, 2008